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Abstract
Adult T-cell leukaemia/lymphoma (ATL) arises from chronic non-malignant human T lym-
photropic virus type-1 (HTLV-1) infection which is characterized by high plasma pro-inflam-
matory cytokines whereas ATL is characterized by high plasma anti-inflammatory (IL-10)
concentrations. The poor prognosis of ATL is partly ascribed to disease-associated immune
suppression. ATL cells have a CD4+CCR4+CD26-CD7- immunophenotype but infected
cells with this immunophenotype (‘ATL-like’ cells) are also present in non-malignant HTLV-1
infection. We hypothesized that ‘ATL-like’ and ATL cells have distinct cytokine producing
capacity and a switch in the cytokines produced occurs during leukemogenesis. Seventeen
asymptomatic carriers (ACs), 28 patients with HTLV-1-associated myelopathy (HAM) and
28 with ATL were studied. Plasma IL-10 concentration and the absolute frequency of IL-10-
producing CD4+ T cells were significantly higher in patients with ATL compared to AC. IL-
10-producing ATL cells were significantly more frequent than ‘ATL-like’ cells. The cytokine-
producing cells were only a small fraction of ATL cells. Clonality analysis revealed that even
in patients with ATL the ATL cells were composed not only of a single dominant clone (puta-
tive ATL cells) but also tens of non-dominant infected clones (‘ATL-like’ cells). The fre-
quency of cytokine-producing cells showed a strong inverse correlation with the relative
abundance of the largest clone in ATL cells suggesting that the putative ATL cells were cyto-
kine non-producing and that the ‘ATL-like’ cells were the primary cytokine producers. These
findings were confirmed by RNAseq with cytokine mRNA expression in ATL cells in patients
with ATL (confirmed to be composed of both putative ATL and ‘ATL-like’ cells by TCR analy-
sis) significantly lower compared to ‘ATL-like’ cells in patients with non-malignant HTLV-1
infection (confirmed to be composed of hundreds of non-dominant clones by TCR analysis).
A significant inverse correlation between the relative abundance of the largest clone and
cytokine mRNA expression was also confirmed. Finally, ‘ATL-like’ cells produced less pro-
and more anti-inflammatory cytokines than non ‘ATL-like’ CD4+ cells (which are predomi-
nantly HTLV uninfected). In summary, HTLV-1 infection of CD4+ T cells is associated with a
change in cytokine producing capacity and dominant malignant clonal growth is associated
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with loss of cytokine producing capacity. Non-dominant clones with ‘ATL-like’ cells contrib-
ute to plasma cytokine profile in patients with non-malignant HTLV-1 infection and are also
present in patient with ATL.
Author summary
Human T-cell lymphotropic virus type-1 (HTLV-1) infection of CD4+ T cells is associated
with a change in their cytokine producing capacity and is responsible for the different
plasma cytokine profiles in patients with adult T-cell leukaemia/Lymphoma (ATL) and
non-malignant HTLV-1 infection. Dominant malignant clonal growth of the infected
CD4+ T cells is associated with loss of cytokine producing capacity. ACs, patients with
HAM and patients with ATL have a common cytokine cluster with positive correlations
between pro- (TNFα and IL-6) and anti- (IL-10) inflammatory cytokines. Plasma IL-10
was higher in the HAM and ATL states compared to AC whilst there was no difference in
pro-inflammatory cytokines. Patients with HAM have raised plasma concentrations of
IFNγ, IL-10 and IL-17 suggesting a complex interaction between these cytokine in HAM
which was not seen in ATL. Aggressive ATL is associated with raised plasma concentra-
tions of pro- and anti-inflammatory cytokines compared to indolent ATL. This cytokine
profile did not precede or predict aggressive ATL. The ‘ATL-like’ infected cells in ACs
and in patients with HAM have lower pro- and higher anti-inflammatory cytokine secre-
tion than non- ‘ATL-like’ cells which are predominantly HTLV-1 uninfected. Putative
ATL cells have little or no cytokine producing capacity. ‘ATL-like’ infected cells from
non-dominant infected clones were present not only in patients with non-malignant
HTLV-1 infection but also ATL. ‘ATL-like’ cells have cytokine producing capacity and
contribute to plasma cytokine profile in patients with non-malignant HTLV-1 infection
and possibly also in ATL.
Introduction
Human T- lymphotropic virus type-1 (HTLV-1) is a complex delta retrovirus infecting an esti-
mated 10 million individuals worldwide [1]. In the majority, infection leads to a chronic
asymptomatic carrier state (AC) but 2% to 6% develop adult T-cell leukaemia/lymphoma
(ATL) and another 3% inflammatory disorders e.g. HTLV-1-associated myelopathy (HAM).
The diagnosis of ATL is based on clinical features, morphology (lymphocytes with characteris-
tic ‘flower cell’ morphology), immunophenotyping (CD3+, CD4+, CCR4+, CD25+, CD26-
and CD7-) and demonstration of dominant HTLV-1 infected clones [2, 3]. ATL is classified
into four subtypes: smouldering, chronic, acute and lymphoma. Smouldering and chronic
ATL are suggested to have an indolent course while acute and lymphoma an aggressive course
[3]. Survival with chemotherapy is poor [4–7] due to primary chemo-refractory disease, or
early relapse or opportunistic infections. [8–11].
Patients with ATL have high plasma concentrations of anti-inflammatory cytokines e.g.
interleukin (IL)-10 [12, 13]. IL-10 is secreted by regulatory CD4+ T cells[14]. CD4+ T cells in
patients with ATL have been shown to have high IL-10 expression [13, 15]. ATL cells express
regulatory T cell-associated markers CD25 and FOXP3 [16–19]. This has led to the assumption
that ATL cells are a regulatory T cell counterpart and mediate an immunosuppressive clinical
state by secreting IL-10. In contrast HAM is characterized by organ damage due to immune
Cytokine profile in HTLV-1 infection and ATL
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activation, and high concentrations of plasma pro-inflammatory cytokines e.g. interferon γ
(IFNγ) [20]. HTLV-1 infected cells secrete IFNγ [21, 22] and directly contribute to the plasma
cytokine profile in HAM. These findings suggest a distinct cytokine producing capacity of
HTLV-1 infected cells in keeping with clinical state.
ATL arises de novo in AC and patients with HTLV-1-associated inflammation such as
HAM, hereafter referred to as non-malignant HTLV-1 infection. HTLV-1-infected cells have a
CD4+CCR4+CD26- immunophenotype; the loss of CD7 expression by these cells differenti-
ates ATL from non-malignant HTLV-1 infection [23–27]. We and others have shown that
‘ATL-like’ HTLV-1-infected (CD4+CCR4+CD26-CD7-) cells are present in patients with
non-malignant HTLV infection. We hypothesize that the cytokine producing capacity of ATL
and ‘ATL-like’ cells are distinct from each other and are directly responsible for the respective
plasma cytokine profile in ATL and non-malignant HTLV-1 infection, and that the change in
cytokine producing capacity reflects malignant transformation from non-malignant HTLV-1
infection to ATL. Pro- and anti-inflammatory cytokine were measured in plasma and cells
(intracellular staining and gene expression by mRNA sequencing) in patients with four differ-
ent HTLV diagnoses: AC; HAM; indolent ATL; aggressive ATL. Clonality analysis of ATL and
‘ATL-like’ cells was performed and the relationship between plasma, cellular cytokine, clonal-
ity and clinical state was studied.
Material and methods
Patients and cells
The patient cohort is based at the National Centre for Human Retrovirology (NCHR) at St
Mary’s Hospital, Paddington, London, UK and the University of Miami School of Medicine,
Miami, USA. Diagnosis of HTLV-1 infection, HAM and ATL was made according to World
Health Organization criteria.
Ethics statement
Patients’ samples are collected and stored in a Communicable Diseases Research Tissue Bank
approved by the UK National Research Ethics Service (references 09/H0606/106 and 15/SC/
0089). Samples at University of Miami School of Medicines are collected under IRB-approved
study "Study of Blood, Tissue and Body Fluids of Viral Associated Malignancies" (EPROST
No. 20030608). Samples are stored under license in accordance with the Human Tissues Act
2004. Samples were collected prior to any systemic therapy in patient with ATL or immune
modulatory treatment in patients with HAM. Baseline demographic and clinical characteris-
tics of the study population are shown in S1 Table.
Peripheral blood mononuclear cells (PBMCs) and plasma were separated from fresh whole
blood by density-gradient centrifugation on Histopaque-1077 (Sigma-Aldrich, St Louis, USA).
Plasma was stored at -80˚C. PBMCs were harvested from the interface, washed in phosphate
buffer saline (PBS, Sigma-Aldrich), cryopreserved in 10% dimethyl sulphoxide (Sigma-
Aldrich) and 90% heat inactivated foetal calf serum (FCS) (Gibco, Carlsbad, USA), and stored
in liquid nitrogen until use.
Electrochemiluminescence assay
Plasma cytokine concentrations of the following nine cytokines/chemokines were measured
using sensitive and specific V_PLEX immunoassays according to the manufacturer’s protocol
(Meso Scale Discovery, Gaithersburg, USA): Human pro-inflammatory cytokines: interferon
gamma (IFNγ), interleukin (IL)-2, IL-6, IL-7, IL-17α, tumour necrosis factor-alpha (TNFα);
Cytokine profile in HTLV-1 infection and ATL
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006861 February 14, 2018 3 / 25
anti-inflammatory cytokine: IL-10 and chemokines: macrophage-derived chemokine (MDC)
also known as CCL22 and C-X-C motif chemokine 10 (CXCL-10) also known as IFNγ-
induced protein 10 (IP-10),.
For samples with detectable concentrations below the limits of quantification missing val-
ues were replaced with 99% of the lowest detectable concentration.
Cellular cytokine assay
Thawed cryopreserved PBMCs were incubated in either complete media (CM) comprising
10% heat inactivated FCS in RPMI with L-glutamine plus 1% Penicillin only, CM with phyto-
hemaggulutinin (PHA, final concentration of 5 μg/mL, Sigma) or CM with 2% cell activation
cocktail (containing phorbol 12-myristate 13-acetate (PMA) and ionomycin, (BioLegend, San
Diego, USA)) at 37˚C, in 5% CO2 at a concentration of 10
6 cells/ 50 μL for 6 hours. Brefeldin A
(BioLegend) was added for the last five hours. All washes were done by suspending cells in
PBS containing 1% FCS followed by centrifugation at 600g for 5 minutes twice. PBMCs were
washed thrice at the end of incubation and stained sequentially with near infrared fixable via-
bility stain followed by flurochrome conjugated monoclonal antibodies against cell surface
markers (CD3, CD4, CD7, CD8 and CCR4) for 30 minutes at room temperature (RT). The
cells were then fixed using fixation buffer from FoxP3 / Transcription Factor Staining Buffer
Set (eBioscience, San Diego, USA). The fixed cells were washed with permeablization buffer
followed by incubation with fluorochrome-conjugated monoclonal antibodies against IL-6,
IL-10, TNFα and IFNγ for 15 minutes at RT. PBMCs were then washed twice and stored at
4˚C in PBS 1% FCS overnight until analysis on Becton Dickinson Fortessa II. A minimum of
20,000 events were recorded for analysis. Compensation was computed using BD FACS diva
software using single staining of Comp ebeads (eBioscience) and checked manually. Fluores-
cence minus one control (antibody cocktail containing all antibodies except one) was used for
gating. Data were analysed by Flowjo software.
Magnetic cell sorting
Magnetic cell sorting was performing by negative selection. Thawed PBMCs were incubated
with primary biotinylated antibodies (CD7, CD26, CD8, CD14, CD15, CD16, CD19, CD36,
CD 56, CD123, TCR γ/δ, CD235a [Miltenyi Biotec Ltd., United Kingdom and Biolegend,
USA]) at 4˚C for 10 min and 107 cells/100 μl. All washes were done by suspending cells in 1%
BSA (Sigma) followed by centrifugation at 600g for 5 minutes twice. Labelled PBMCs were
washed and incubated with 30% dilution of streptavidin conjugated microbeads at a final con-
centration of 107 cells/100 μL. Microbead-conjugated PBMCs were washed and magnetically
sorted twice on LS Columns (Miltenyi Biotec Ltd) according to the manufacturer’s directions.
The flow-through containing CD3+CD4+CD7-CD26-cells, of which 99% were CCR4+, was
washed twice. Of these cells, 104 cells were used to check for purity by flow cytometry and the
remainder were used for HTLV-1 proviral load quantification and clonality analysis.
HTLV-1 proviral load (PVL) quantification
Genomic DNA was extracted from PBMCs and sorted CD4+ T cell subsets using QIAamp
DNA mini kit (Qiagen, Hilden, Germany). The proviral load was determined by real-time
PCR as previously described [28].
Cytokine profile in HTLV-1 infection and ATL
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Ligation mediated PCR followed by HTS
Clonality analysis was performed using linker-mediated (LM)-PCR, high-throughput sequenc-
ing analysis of HTLV-1 integration sites according to the method previously described [29].
Random fragments of 1 μg genomic DNA (100 ng of sample DNA mixed with 900 ng of unin-
fected DNA from Jurkat cells) were generated by sonication and ligated to custom, partially
double-stranded, DNA adaptors. Nested PCR using specific primers was performed to selec-
tively amplify adaptor-ligated DNA fragments abutting the HTLV-1 3’ LTR. The PCR prod-
ucts from each sample had two unique 8bp multiplexing barcodes and were pooled for
sequencing. Paired-end 150-base reads were generated on an Illumina MiSeq. The reads were
de-multiplexed using the MiSeq reporter. The linker and primer sequences are listed in S2
Table.
The in silico analysis was conducted in shell and R environment. Read 1 and Read 2 were
aligned to reference human (hg38, UCSC) and HTLV-1 genomes using Bowtie2[30]. The
number of unique integration sites (clones) and the relative and absolute abundance of each
unique integration site (clonal size) were calculated as previously described [29].
RNA sequencing
RNA was extracted from MACS-sorted cells using Qiagen Allprep DNA/RNA column-based
extraction kits (Qiagen) as per the manufacturer’s instructions. RNA-seq was performed on
DNase-treated samples using TruSeq Stranded mRNA Library Prep Kit (Illumina, United
States) as per the manufacturer’s instructions. All sorted cells had the highest RNA quality
(> 100 ng RNA and RNA quality score 8). All sequencing was performed using 50 nucleo-
tide paired-end reads on an Illumina HiSeq 4000 instrument at the Imperial biomedical
research centre (BRC) genomics facility, London, United Kingdom.
Analysis of T-cell receptor clonality. MiXCR software [31] with standard settings was
used to identify TCR alpha and beta CDR3-containing reads present in the RNA sequencing
data, generating a list of CDR3s (individual clones) and their relative abundances (clonal
fraction = reads of individual clone/reads of all clones). Due to allelic exclusion, each T cell
clone should only express one beta chain[32], therefore the most abundant beta clonotype (if
present, otherwise alpha) was used to define the relative abundance of the clonal T cell in each
subject.
Mapping and identification of differentially expressed genes. Before read mapping,
clean reads were obtained by removing reads that contained adapter or poly-N, and low qual-
ity reads from raw data by using Trimmomatic, a flexible read trimming tools (Version 0.36,
[33]). At the same time, Q20, Q30, and GC contents of the clean data were calculated using
FastQC (Babraham Bioinformatics). All the downstream analyses were based on the high qual-
ity clean data. The normalized and differential gene expression was performed using the new
Tuxedo pipeline[34]. The clean reads were aligned to the human genome (version: GRCH38)
using the HISAT2 program (V2-2.0.1). We applied Stringtie (Version 0.36) and Ballgown algo-
rithms to identify the significantly differentially expressed genes (p<0.05). Cytokine, chemo-
kine and their receptors gene expression was extracted from the differential gene expression
data. Hierarchical clustering was performed to generate an overview of the characteristics of
the cytokine gene expression profiles, based on values of significantly differentially expressed
transcripts.
Statistics
Statistical analysis was performed using Graphpad Prism software. The significance of differ-
ence in continuous variables between multiple patient groups was determined by a Kruskal-
Cytokine profile in HTLV-1 infection and ATL
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Wallis test with Dunn post-test analysis. The significance of difference in continuous variables
between two cell subsets was determined using a Wilcoxon signed-rank test. The significance
of difference in contingency variables was determined by a chi-squared test. Differences were
considered statistically significant if p<0.05. The correlation between two continuous vari-
ables was determined by a non-parametric Spearman test. The Spearman correlation was con-
sidered significant for p<0.05 and showing a trend if the p value was between 0.05 and 0.1.
A classification tree was constructed to identify the hierarchical organisation of plasma
cytokine concentration in ACs, patients with HAM and patients with ATL. The classification
tree was produced using a Recursive Partitioning and Regression Trees (RPART) analysis in R.
The network analysis was performed using NodeXL. In the analysis, absolute CD3+,
CD4+ and CD8+ cell counts and PBMC PVL were used as cellular variables, and plasma cyto-
kine concentrations were used as cytokine variables. The cellular and cytokine variables were
used as edges of the network while the Spearman correlates between nodes were used as verti-
ces. Vertices with at least a significant trend on Spearman correlation (p<0.1) were included.
The layout was performed using Harel-Koren Fast multiscale.
Results
Plasma cytokine profile in non-malignant HTLV-1 infection and ATL
The relative and absolute frequencies of CD3+, CD4+ T cells and HTLV-1 PVL in PBMCs
were significantly higher in patients with ATL compared to ACs or patients with HAM
(Table 1). Patients with HAM had significantly higher plasma concentrations of IFNγ,
CXCL10, IL-2 and IL-17 (pro-inflammatory cytokines) compared to ACs and patients with
ATL (Fig 1A–1D). Patients with ATL and patients with HAM had significantly higher plasma
concentrations of the anti-inflammatory cytokine IL-10 compared to ACs (Fig 1E). There was
no significant difference in plasma concentrations of IL-6, IL-7, CCL22 and TNFα between
the three patient groups (Fig 1F–1I). The median plasma concentrations of IL-6 and TNFα in
all three patient groups were near the upper limit of the manufacturer’s normal human range
while those of CCL22, IL-2 and IL-7 were near the lower limit.
Patients with aggressive ATL had significantly higher TNFα, IL-6 and IL-10 plasma concen-
trations than those with indolent ATL (Fig 2A–2C). There was no significant difference in
plasma concentrations of IFNγ, CXCL10, CCL22, IL-2 and IL-7 between ATL subtypes as
shown in S1 Fig.
The plasma chemokine and cytokine concentrations, of four patients with HAM who devel-
oped de novo aggressive ATL and two patients with indolent ATL who progressed to aggressive
ATL, were measured at aggressive ATL diagnosis and at 3–12 months earlier. Plasma TNFα,
IL-6 and IL-10 concentrations were significantly higher at diagnosis, with median increases of
1.9-fold; 3.7-fold and 7.1-fold respectively (Fig 2D). There was a large variance in changes of
plasma IFNγ concentrations.
In summary, patients with HAM have the highest concentrations of pro-inflammatory
cytokine and ACs had the lowest IL-10 plasma concentrations. Patients with aggressive ATL
had higher plasma concentrations of TNFα, IL-6 and IL-10 compared to patients with indolent
ATL. These higher plasma concentrations did not precede malignant progression.
Network and classification tree analysis of immune profile in non-
malignant HTLV-1 infection and ATL
Network analysis was performed to better understand the interaction between cellular and
plasma immune markers. The absolute frequency of CD3+, CD4+ T cells and PVL were
Cytokine profile in HTLV-1 infection and ATL
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significantly positively correlated with each other in patients with HAM or ATL (Fig 3A and
3B). There were also significant positive correlations between the plasma concentrations of
TNFα, IL-6 and IL-10 in all three diagnostic groups (Fig 3A–3C). The plasma concentration of
IL-10 correlated significantly with IFNγ in patients with ATL and to a lesser extent with both
IFNγ and IL-17 in patients with HAM.
Table 1. T-cell subsets and proviral load in AC, HAM and ATL.
Patient group Parameter CD3 CD4 CD8 PVL (copies
per 100
PBMCS)
Absolute count
(10^6/uL)
Relative count (%
lymphocytes)
Absolute count
(10^6/uL)
Relative count (%
lymphocytes)
Absolute count
(10^6/uL)
Relative count (%
lymphocytes)
AC (n = 17) Minimum 881 61.4 539 30 194 12 <0.1
25%
Percentile
1139 67 860 45 289 15 0.7
Median 1454 73 989 53 385 19 2.8
75%
Percentile
1852 79 1260 58 518 27 18.9
Maximum 2970 87 1563 66 1470 42 27.9
Mean 1458 73 1049 51 461 22 9.4
Std.
Deviation
631 8 301 9 360 10 10.4
Std. Error 158 2 78 2 90 2 2.5
HAM (n = 28) Minimum 723 59 264 22 232 17 0.4
25%
Percentile
1112 74 678 44 342 22 4.4
Median 1347 79 864 50 508 25 6.9
75%
Percentile
2057 84 1301 55 855 36 12.6
Maximum 3768 95 2368 60 1495 73 28.8
Mean 1644 78 1012 48 633 30 9.0
Std.
Deviation
789 9 522 10 371 13 7.2
Std. Error 147 2 97 2 69 2 1.3
ATL (n = 28) Minimum 574 38 334 22 160 1 2.0
25%
Percentile
2345 81 1454 58 287 3 20.3
Median 6494 93 5499 83 366 8 29.8
75%
Percentile
11868 95 10600 91 531 16 64.6
Maximum 91000 99 11612 94 1252 31 276.2
Mean 14534 85 5695 73 446 10 54.3
Std.
Deviation
24674 16 4343 22 263 9 59.9
Std. Error 5384 4 1024 5 62 2 11.8
Significance of
difference?
AC vs
HAM
Ns Ns ns ns ns ns ns
AC vs ATL     ns  
HAM vs
ATL
    ns  
 denotes p<0.05,
 denotes p<0.001, ns denotes not significant
AC denotes asymptomatic carriers, HAM denotes HTLV-1-associated myelopathy, ATL denotes adult T-cell leukaemia/lymphoma
https://doi.org/10.1371/journal.ppat.1006861.t001
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A classification tree analysis was performed on plasma cytokine concentrations to identify
the cytokine profile which best differentiated AC, HAM and ATL states. A plasma IL-10
concentration < 0.16 pg/mL identified AC with a 64.7% sensitivity and 73% specificity as
shown in Fig 3D. A plasma IL-17 concentration <1 pg/mL or if the IL-17 concentration was
>1 pg/mL an IL-10 concentration of>0.8 pg/mL identified ATL with 78.5% sensitivity and
85% specificity whilst an IL-17 concentration of 1 pg/mL with an IL-10 concentration
between 0.16 and 0.8 pg/mL identified HAM with 82.1% sensitivity and a specificity of 71.8%.
In summary, a positive correlation between the plasma concentrations of specified pro- and
anti-inflammatory cytokines was present in all three HTLV-1 patient groups. Together, the
plasma concentrations of IL-10 and IL-17 discriminated between the clinical states associated
with HTLV-1 infection.
Cellular cytokine studies in non-malignant HTLV-1 infection and ATL
To identify the cellular source of the cytokines identified in plasma, the cytokine producing
capacity of monocytes, CD4+ and CD8+ T cells was studied. Intracellular cytokine staining for
Fig 1. Plasma cytokine concentration in non-ATL HTLV-1 infection and ATL. A-I) Aligned column plots of plasma cytokine/chemokine concentrations in
patients with non-ATL HTLV-1 infection and ATL. The bar represents median values. The continuous line and shaded area shows manufacturer supplied
median and range in healthy individuals. Statistical analysis: Kruskal-Wallis test with Dunn post-test, 95% confidence interval.  denotes p<0.05,  denotes
p<0.01,  denotes p<0.001.
https://doi.org/10.1371/journal.ppat.1006861.g001
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TNFα, IFNγ, IL-6 and IL-10 was performed in 10 ACs, 11 patients with HAM and 10 with
ATL (four with indolent and six with aggressive ATL). The gating strategy to detect cytokine
producing cells is shown in S2 Fig. The relative and absolute frequencies of cells secreting each
cytokine are shown as percentages and cell count per litre.
Although there was no difference in the relative frequency of IL-10+ CD4+ cells (Fig 4E)
their absolute frequency was higher in patients with ATL compared to AC and HAM (Fig 4A).
The relative and absolute frequency of IL-6+ CD4+ cells did not differ by disease state (Fig
4B–4F). The absolute frequencies of TNFα+ CD4+ T-cells were the same in each group (Fig
4C) but TNF+ cells made up a significantly lower percentage of all CD4+ T cells in patients
with ATL compared to non-malignant HTLV-1 infection (Fig 4G). Finally, although the abso-
lute frequency of CD4+ T-cells secreting IFNγ was increased in ATL (Fig 4D), the relative fre-
quency of these cells was significantly lower in patients with ATL than in ACs and patients
with HAM (Fig 4H). In patients with ATL the median relative frequencies of TNFα, IFNγ, IL-
6 and IL-10 secreting CD4+ cells were 5%, 1.7%, 0.6% and 0.3% respectively. The frequencies
of TNFα, IFNγ, IL-6 and IL-10-secreting CD8+ cells and monocytes (except IFNγ, which is
not secreted by monocytes) did not differ between diagnostic groups as shown in S3 Fig.
Fig 2. Plasma cytokine concentrations in ATL. A-C) Aligned column plots of plasma cytokine/chemokine concentrations in indolent and aggressive ATL. D)
Box plots of fold change in six patients with aggressive ATL at diagnosis and at 3–12 months pre-diagnosis. The bar represents median values. Statistical
analysis: Kruskal-Wallis test with Dunn post-test, 95% confidence interval and Wilcoxon signed rank test.  denotes p<0.05,  denotes p<0.01,  denotes
p<0.001.
https://doi.org/10.1371/journal.ppat.1006861.g002
Cytokine profile in HTLV-1 infection and ATL
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In summary, although the absolute frequency of the cytokine-producing CD4+ T-cells was
greater in patients with ATL these make up only a minority of their CD4+ T cells suggesting
that ATL cells are in general not secreting these cytokines.
Cytokine producing capacity of ATL and ‘ATL-like’ cells
CD4+ T cells are the dominant reservoir of infected cells in both non-malignant HTLV-1
infection and ATL [23, 35]. The infected cells are derived from thousands of non-dominant
clones in non-malignant HTLV-1 infection and from a dominant clone on a polyclonal back-
ground of non-dominant clones in ATL [29, 36, 37]. To further characterise the ATL and
‘ATL-like’ cells, their cytokine producing capability was determined. ATL cells have a CD4
+CCR4+CD26-CD7- immunophenotype and ‘ATL-like’ cells are present in non-malignant
HTLV-1 infection. The CD4+CCR4+CD7- immunophenotype was used to study the cytokine
producing capacity of ATL cells as>99% of CD4+CCR4+CD7- cells were also CD26-.
The relative (Fig 5A) and absolute frequencies (Fig 5B) of CD4+CCR4+CD7- T cells were
significantly higher in patients with ATL compared to non-malignant HTLV-1 infection whilst
there was no difference in the absolute frequency of non-CCR4+CD7- CD4+ T cells (Fig 5B).
Fig 3. Network and classification tree analysis of plasma cytokine concentration in non-ATL HTLV-1 infection and ATL. Network analysis
of absolute T-cell subset count, HTLV-1 PVL and plasma cytokine concentration using at least significant Spearman correlation trends is shown
for patients with ATL (A), HAM (B) and AC (C). The green and red lines denote positive and negative correlations respectively. The continuous
and broken line denote statistically significant and trend correlations. The prune classification tree to classify diagnosis of AC, HAM and ATL
on the basis of IL-10 and IL-17 concentration is shown in figure D. The percentage shows the distribution of all patients into different arms
whilst the three decimal numbers shown specificity of each classification for diagnosis of AC, ATL and HAM respectively.
https://doi.org/10.1371/journal.ppat.1006861.g003
Cytokine profile in HTLV-1 infection and ATL
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Fig 4. CD4+T-cell cytokine producing profile in non-ATL HTLV-1 infection and ATL. A-H) Bar column plots
showing absolute and relative frequency of CD4+T cells in asymptomatic carriers (AC), patients with HTLV-1
associated myelopathy (HAM) and adult T-cell leukaemia/lymphoma (ATL). The bar represents mean values and
error bar the standard deviation. Statistical analysis: Kruskal-Wallis test with Dunn post-test, 95% confidence interval
and Wilcoxon signed rank test.  denotes p<0.05,  denotes p<0.01,  denotes p<0.001.
https://doi.org/10.1371/journal.ppat.1006861.g004
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Fig 5. CD4+CCR4+CD7- T cells as marker of ‘ATL-like’ infected and ATL cells. Bar column plots showing the
absolute frequency and relative of CD4+CCR4+CD7- (A & B) and non CCR4+CD7- CD4+T cells in AC, patients with
HAM and ATL showed highly significant increased frequency of CD4+CCR4+CD7- T cells in patients with ATL
compared to AC and HAM. The bar represents median values. Statistical analysis: Kruskal-Wallis test with Dunn post-
test, 95% confidence interval and Wilcoxon signed rank test. C) XY scatters plots showing significant positive
correlation of PVL with relative and absolute frequency of CD4+CCR4+CD7- T cells. The line represents linear
regression line with rho and R for Spearman and linear regression correlate respectively.  denotes p<0.05,  denotes
p<0.01,  denotes p<0.001.
https://doi.org/10.1371/journal.ppat.1006861.g005
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HTLV-1 PVL significantly and positively correlated with the relative (rho = 0.87, p<0.0001)
and absolute (rho = 0.88, p<0.0002) frequencies of CD4+CCR4+CD7- cells but not the
absolute frequency of non-CCR4+CD7- CD4+ T cells (rho = 0.20, p = 0.27). This confirms
CD4+CCR4+CD7- cells as marker of ATL and ‘ATL-like’ HTLV-1 infected cells in patients
with ATL and non-malignant HTLV-1 infection respectively. HTLV-1 infection leads to an
absolute increase in ‘ATL-like’ cells in patients with non-malignant HTLV-1 infection. The
relative and absolute frequency of ATL cells was actually higher than non-ATL CD4+T cells
in patients with ATL but there was no difference between ‘ATL-like’ and non- ‘ATL-like’
CD4+ T cells in non-malignant HTLV-1 infection.
The absolute frequency of IL-10-producing CD4+CCR4+CD7- cells in patients with ATL
was significantly higher compared to ACs and HAM (Fig 6A). The relative frequency of IL-
10-producing CD4+CCR4+CD7- cells in patients with ATL was lower compared to AC and
HAM (Fig 6E). The absolute frequency of IL-6-producing CD4+CCR4+CD7- cells in patients
with ATL was higher compared to ACs and patients with HAM (Fig 6B). The relative fre-
quency of IL-6-producing CD4+CCR4+CD7- cells in patients with ATL was low compared to
AC and patients with HAM (Fig 6F). The absolute frequency of CD4+CCR4+CD7- T cells
producing TNFα (Fig 6C) or IFNγ (Fig 6D) was significantly higher in patients with ATL com-
pared to ACs whilst there was a trend when compared to patients with HAM (p = 0.11 and
p = 0.10 respectively). However, the relative frequencies of TNFα and IFNγ producing
CD4+CCR4+CD7- cells were significantly lower in patients with ATL compared to ACs and
HAM as shown in Fig 6G and 6H. The median relative frequencies of TNFα, IFNγ, IL-6 and
IL-10 secreting CD4+CCR4+CD7- T cells in patients with ATL were 3.3%, 1.7%, 0.2% and
0.3% respectively.
The CD4+ T cells which are not CCR4+CD7- are a mixture of predominantly uninfected
(82%) and infected cells (18%) [23]. The uninfected non-CCR4+CD7- CD4+T cells are a mix
of naïve and memory CD4+T cells. CD4+naïve T cells have been shown to be depleted in
HTLV-1 infection. In addition, naïve CD4+T cells produce less cytokine than memory T cells
suggesting that the cytokine producing capacity of non-CCR4+CD7- CD4+T cells is mainly
derived from uninfected memory T cells. The absolute and relative frequencies of pro- inflam-
matory cytokine (TNFα, IFNγ and IL-6) producing CCR4+CD7- cells (i.e. ‘ATL-like’ infected
cells) was lower than in non-CCR4+CD7- CD4+ T cells (i.e. predominantly HTLV-1 unin-
fected memory cells, Fig 6F–6H) in AC and patients with HAM. The absolute and relative fre-
quencies of CD4+CCR4+CD7- cells producing the anti-inflammatory cytokine IL-10 was
higher compared to non-CCR4+CD7- CD4+T cells in ACs and patients with HAM as shown
in Fig 6A–6H. The relative frequency of pro-inflammatory cytokine producing CD4+CCR4
+CD7- cells was lower than non-CCR4+CD7- CD4+T cells whilst the absolute frequency of
IL-10 secretion was higher in patients with ATL. The absolute and relative frequencies of
TNFα, IFNγ, IL-6 and IL-10 secreting non-CCR4+CD7- CD4+cells did not differ significantly
between the three clinical groups.
In summary, patients with non-malignant HTLV-1 infection have an increased frequency
of CD4+CCR4+CD7- (‘ATL-like’ infected cells) which correlates strongly with PVL. There is a
further increase in these cells in patients with ATL. These cells are capable of producing pro-
and anti-inflammatory cytokines. However, CD4+CCR4+CD7- cells had lower pro- and
higher anti-inflammatory cytokine producing capacity compared to non-CCR4+CD7-
CD4+T cells (predominantly uninfected cells) in non-malignant HTLV-1 infection. The abso-
lute frequencies of not only IL-10 cytokine secreting CD4+CCR4+CD7- cells but also TNFα,
IFNγ and IL-6 secretors were higher in ATL compared to non-malignant HTLV-1 infection.
However, the cytokine producing cells made up only a tiny fraction of CD4+CCR4+CD7- T
cells in patients with ATL. This suggests that at some point in the transformation of ‘‘ATL-like’
Cytokine profile in HTLV-1 infection and ATL
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Fig 6. CD4+T-cell subsets cytokine producing profile in non-ATL HTLV-1 infection and ATL. A-H) Bar column
plots showing absolute and relative frequency of CCR4+CD7- and non CCR4+CD7- CD4+T-cell subset in
asymptomatic carriers (AC), patients with HTLV-1 associated myelopathy (HAM) and adult T-cell leukaemia/
lymphoma (ATL). The bar represents mean values and error bar the standard deviation. Statistical analysis: Kruskal-
Wallis test with Dunn post-test, 95% confidence interval and Wilcoxon signed rank test.  denotes p<0.05,  denotes
p<0.01,  denotes p<0.001.
https://doi.org/10.1371/journal.ppat.1006861.g006
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to ‘ATL’ cells CD4+CCR4+CD7- lose their cytokine producing capacity and that they are not
the source of the plasma cytokines observed in ATL. The question remains whether the cyto-
kine-secreting ‘ATL’ cells are a sub-population of the malignant clone or ‘ATL-like’ cells.
Clonality within CD4+CCR4+CD7- T cells in ATL
Patients with ATL have a putative dominant clone on a polyclonal background. The dominant
cell population in ATL is CD4+CCR4+CD7-. In order to determine the likely clonal origin of
cytokine secreting CD4+CCR4+CD7- T cells clonality analysis was performed within sorted
CD4+CCR4+CD7- T cells in four patients with aggressive ATL. In these patients, the CD4
+CCR4+CD7- cells population had a median of 41 clones with the largest clone contributing a
median 88% of the HTLV-1 infection burden as shown in Table 2. Thus, CD4+CCR4+CD7-
cells in patients with ATL are derived not exclusively from a single dominant clone (putative
ATL cells) but also from tens of non-dominant infected clones i.e. ‘ATL-like’ cells. There was a
perfect negative correlation (rho = -0.99, p<0.0001) between the relative frequencies of cyto-
kine secreting cells and the relative abundance of the largest clone further supporting the sug-
gestion that ‘ATL-like’ infected cells from non-dominant clones are cytokine producing whilst
the cells from the dominant clone secrete little or no cytokines in patients with ATL.
Inflammatory transcriptome of CD4+CCR4+CD7- cells in patients with
non-malignant HTLV-1 infection and ATL
In order to determine the global and confirm the deferential cytokine profile of CD4+CCR4
+CD7- cells in patients with non-malignant HTLV-1 infection and ATL, we studied the
expression of cytokines, chemokines and their receptors by mRNA sequencing of sorted CD4
+CCR4+CD7- T cells in eight patients with non-malignant (four AC and four patients with
HAM) and eight with ATL.
Clonality within CD4+CCR4+CD7- cells in patients with non-malignant and ATL.
Clonality analysis within these sorted cells was performed by extracting T-cell receptor (TCR)
alpha and Beta sequences using MiXCR pipeline ([31]).
There was no difference in total and reads aligned to TCR-Beta and TCR-alpha in patients
with non-malignant HTLV-1 infection and ATL as shown in Table 3. A median of 0.009%
and 0.0046% of all reads were aligned to TCR-Beta sequence in patients with ATL and non-
malignant HTLV-1 infection respectively. A significantly larger number clones were detected
within ‘ATL-like’ cells in patients with non-malignant (median = 341) HTLV-1 infection com-
pared to ATL (median = 21, range, p = 0.0002) whilst the clonal fraction of the two largest
Table 2. Clonality and cytokine producing profile of CD4+CCR4+CD7- T cells in patients with ATL.
Patient
code
Clinical state Proviral load (copies per 100
cells)
Total number of HTLV-1 infected
clones
Relative abundance of the largest
clones (%)
Cells secreting any
cytokine (%)
ATL12 Aggressive
ATL
178.4 41 82 28
ATL22 Aggressive
ATL
165.7 34 94 6
ATL197 Aggressive
ATL
179.4 40 89 16
LGL2 Aggressive
ATL
229.0 50 86 23
Median na 178.9 41 88 19
https://doi.org/10.1371/journal.ppat.1006861.t002
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clones was significantly lower in patients with non-malignant (median = 0.07) compared to
ATL (median = 0.99, p = 0.0012) as shown in Table 3. Six out of eight patients with ATL had a
single clone contributing more than 0.94 of the total by TCR-Beta clonality analysis. One
patient with ATL (LFA) had two similar size clones whilst one (LGV) had very low alignment
to TCR Beta sequences. Both these patients had a single clone (LFA = 0.92 and LGV = 0.95
respectively) by TCR-alpha clonality analysis. This suggests that the lower clonal fraction
by TCR-Beta clonality in these patients is due to bi-allelic TCR-Beta expression and low
TCR-Beta mapped reads respectively. In all but one patient with non-malignant infection the
two largest clones contributed less than 0.15 of the total clonal fraction. One patient with non-
malignant infection (HKU) had two large clones by both TCR-Beta and TCR-alpha clonality
analysis. These data confirm that CD4+CCR4+CD7- cells are derived from a large number of
non-dominant clones in patients with non-malignant HTLV-1 infection and a single domi-
nant clone on a background of non-dominant in patients with ATL.
Differential cytokine expression within CD4+CCR4+CD7- cells in patients with non-
malignant HTLV-1 infection and ATL. We performed differential inflammatory transcrip-
tome expression (cytokines, chemokines and their receptor mRNA expression) within ‘ATL-
like’ cells in patient with non-malignant HTLV-1 infection and ATL. A total of 127 inflamma-
tory transcripts were detected in at least one patient as shown in S3 Table. Seventeen inflam-
matory transcripts were differentially expressed (p<0.05) in patients with non-malignant
infection compared to ATL, out of which ten (CCL5, CXCR3, CXCR4, CXCR5, CCR5, CCR6,
IFNG, TNF, ICAM1 and IL-10RA) were expressed 2-fold higher in patient with non-malig-
nant compared to ATL infection.
The gene expression of TNFα, IFNγ and IL-10 within ‘ATL-like’ cells was higher in patients
with non-malignant infection compared to ATL (p = 0.048, p = 0.031 and = 0.056 respectively)
in keeping with relative frequencies of cytokine secreting cells by intracellular cytokine stain-
ing. The gene expression of TNFα and IFNγ within ‘ATL-like’ cells was significantly higher
than IL-6 (p< 0.01 and p< 0.01 respectively) and IL-10 (p< 0.01 and p< 0.01 respectively) in
both patients with non-malignant HTLV-1 infection and ATL as shown in Fig 7A and in
keeping with the relative frequencies of cytokine secreting cells by intracellular cytokine stain-
ing. The gene expression of TNFα, IFNγ and IL-10 showed significant negative correlation
with the clonal fraction of the two largest clones in patients with non-malignant and ATL
(p = 0.048, p = 0.031 and = 0.056 respectively) as shown in Fig 7B. Unsupervised hierarchical
clustering of all, as well as the differentially expressed, inflammatory transcriptome showed
three clusters: a cluster of ATL (seven out of eight patients with ATL), a non-malignant cluster
(six out of eight patients with non-malignant) and an overlapping cluster of three patients
(one each with indolent ATL, non-malignant with large clones (HKU) and non-malignant
without large clones) as shown in S4 Fig.
In summary clonality analysis confirmed that the CD4+CCR4+CD7- cells were derived not
only from a single dominant clone (putative ATL cells) but also from multiple non-dominant
clones (‘ATL-like’) cells in patients with ATL whilst in non-malignant HTLV-1 infection mul-
tiple non-dominant clones contribute to these ‘ATL-like’ cells. A large number of inflamma-
tory transcripts are expressed within CD4+CCR4+CD7- cells in patients with non-malignant
HTLV-1 infection and in patients with ATL, of which ten (CCL5, CXCR3, CXCR4, CXCR5,
CCR5, CCR6, IFNG, TNF, ICAM1 and IL-RA) were expressed 2-fold higher in patient with
non-malignant compared to ATL. Hierarchical clustering of cytokine expression shows three
patterns: ATL, non-ATL and an overlap cluster. TNFα, IFNγ and IL-10 gene expression within
CD4+CCR4+CD7- in patients with ATL was lower compared to non-malignant HTLV-1
infection and correlated inversely to size of largest clone.
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Fig 7. Cytokine mRNA expression profile in non-malignant HTLV-1 infection and ATL. Column plots (A) shows
normalized FPKM expression of TNF, IFN, IL-6 and IL-10 linked by patient samples. Statistical analysis: Kruskal-
Wallis test with Dunn post-test, 95% confidence interval and Wilcoxon signed rank test. Scatterplot (B) shows
correlation between normalized FPKM expression and clonal fraction of two largest clones. Statistical analysis:
Spearman correlation.  denotes p<0.05,  denotes p<0.01,  denotes p<0.001.
https://doi.org/10.1371/journal.ppat.1006861.g007
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Discussion
The study of cellular and plasma immune markers provides an important insight into the
pathophysiology of HTLV-1 infection associated clinical states. The differential, network and
classification tree analysis of plasma immune markers presented here were in keeping with
previously published data. The role of pro-inflammatory cytokines in the pathogenesis of
HAM [20, 38–43] was confirmed by higher plasma concentrations of pro-inflammatory cyto-
kines (IFN, IL-17, IL-2 and CXCL10) in patients with HAM.
A positive correlation between plasma concentrations of pro- (TNFα and IL-6) and anti-
(IL-10) inflammatory cytokine was present both in patients with non-malignant (AC and
patients with HAM) HTLV-1 infection and those with ATL. This correlation has previously
been reported in AC and patients with HAM [20] but not ATL and represents the immune
consequence of HTLV-1 infection irrespective of clinical state. The pro-inflammatory cytokine
concentrations were similar in AC, patients with HAM and patients with ATL but high com-
pared to the published normal range whilst the anti-inflammatory cytokine concentration was
higher in patients with HAM or ATL compared to AC. Patients with aggressive ATL had
higher plasma pro- and anti-inflammatory cytokines concentrations compared to patients
with indolent ATL. This is in keeping with the results of a Japanese study which found high
plasma IL-6 and IL-10 concentrations (anti-inflammatory cytokines) in patients with aggres-
sive ATL compared to ACs and patients with indolent ATL[12] and a Middle-Eastern study
which showed high plasma IL-10 concentrations in patients with ATL[13]. A recent Brazilian
study also showed raised plasma IL-10 in patients with HAM compared to AC [20]. These data
confirmed not only that ATL is associated with high anti-inflammatory plasma cytokine con-
centrations, especially in aggressive disease, but also that this is seen in patients with HAM.
Importantly the plasma cytokine profile is established early and rather than immediately pre-
ceding or predicting aggressive ATL.
In the UK cohort, Incident ATL has occurred predominantly amongst patients with HAM
[44]. Similarly, a South American study highlighted the high co-incidence of HAM and ATL
[45]. The higher plasma IL-10 which positively correlated with IFNγ concentrations was pres-
ent in both patients either with ATL or with HAM. The role of these interactions in progres-
sion to ATL merit further investigation.
Pro and anti-inflammatory cytokines are secreted by a variety of cells including macro-
phages, monocytes, lymphocytes and non-haematopoietic cells. The overwhelming majority of
HTLV-1 infection burden is within CD4+T cells in both non-malignant and ATL infection [6,
23, 24, 35]. The cytokine producing capacity of monocytes and lymphocytes might help eluci-
date the direct contribution of HTLV-1 infected, ATL and micro-environment cells to the
plasma cytokine profile. The cytokine producing capacity of CD4+T cells has been shown to
contribute to the plasma cytokine profile in ATL[13, 15]. The absolute frequency of IL-10
secreting CD4+T cells in patients with ATL was higher compared to AC and HAM. CD4+T
cells are a mixture of infected and uninfected cells in patients with HTLV-1 infection.
In ATL the majority of infected cells are derived from a single dominant leukemic clone
amongst thousands of non-dominant clones whilst thousands of non-dominant clones of vary-
ing size contribute to the total infection burden in non-ATL HTLV-1 infection [29, 36, 37, 46].
CD4+CCR4+CD26-CD7- cells have been shown to harbour the dominant clone in ATL and
these cells are also present in non-malignant HTLV-1 infection[23, 27, 47, 48]. We have dem-
onstrated that these cells are made up of hundreds of non-dominant clones (‘ATL-like’ cells)
in patients with non-malignant HTLV-1 infection and a single dominant clone (putative ATL
cells) amongst tens of smaller non-dominant clones (‘ATL-like’ cells) in patients with ATL.
This is different to previous work, which showed infected cells with an ‘ATL-like’
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immunophenotype harbour only dominant clones, is due to the higher sensitivity and quanti-
fication of our clonality techniques (LMPCR-HTS and TCR sequencing compared to inverse
PCR).
The cellular cytokine producing profile, inflammatory transcriptome and clonality within
ATL and ‘ATL-like’ cells was directly studied for the first time. CD4+CCR4+CD7- cells had
pro- and anti-inflammatory cytokines producing capacity at protein (intracellular cytokine
staining) and mRNA (RNA sequencing) level in non-malignant HTLV-1 infection and in
ATL. The CD4+CCR4+CD7- cytokine producing capacity of not only anti- but also pro-
inflammatory cytokines was higher in patients with ATL compared to AC and patient with
HAM. These findings appear to be contrary to the assumption that these cells produce only
anti-inflammatory cytokine based on the extrapolation of the high plasma IL-10 concentration
and high frequencies of IL-10-producing CD4+cells in patients with ATL findings. However,
the cytokine producing capability of CD4+CCR4+CD7- cells in patients with ATL, measured
by both ICS and RNA sequencing, was extremely low raising the suspicion the cytokine pro-
ducing cells might not be the putative ATL cells but the ‘ATL-like’ cells. This was supported by
the clonality analysis. The size of the dominant clone by LMPCR-HTS and TCR clonality cor-
related inversely with the frequency of cells secreting any cytokines by ICS and cytokine
mRNA expression. Very few studies have been performed to study directly the cytokine pro-
ducing capability of ATL and ‘ATL-like’ infected cells. CD4+CCR4+CD25+ (HTLV-1
infected) cells have been showed to be capable of secreting IFNγ in patients with HAM (21, 22,
40]. Only a minority of CD4+CD25+ cells in patients with ATL have been shown to be capable
of cytokine secretion [49]. The cause and implication of the raised cytokine producing ‘ATL-
like’ cells of non-dominant clones in patients with ATL is not completely clear and needs fur-
ther investigation.
The higher anti- and lower pro- inflammatory cytokine producing capability of ‘ATL-like’
infected cells compared to HTLV-1 uninfected CD4+ T cells was demonstrated in patients
with non-malignant HTLV-1 infection. This finding could be due to expansion of rare
CD4+T-cell subsets or a change in the differentiation of host cells by HTLV-1 infection.
CD4+CCR4+ and CD4+CD7- T cells have been shown to have Th2 and regulatory T cells
cytokine skewing in healthy individuals [50–52]. These suggest HTLV-1 infection might select
the differentiation and immune function of infected cells.
The main limitation of the current study is that the experiments were performed only on
PBMCs and thus the cytokine profile of non-circulating lymphocytes in lymph nodes and
other tissues remains to be elucidated. Secondly the evidence for cytokine producing capability
of dominant and non-dominant clone(s) in patient with ATL is indirect. Direct evidence
would require unusual volumes of patient blood samples as well as technical advances
(improving purity and yield of sorting techniques). Hence, the indirect correlation data of
cytokine producing capacity by ICS and clonality by LMPCR-HTS was confirmed by an inde-
pendent technique (RNA sequencing to study inflammatory transcriptome and TCR clonality)
in the same and in additional patient samples.
Conclusion
There is an absolute increase in ‘ATL-like’ cells made up of non-dominant infected clones in
patients with non-malignant HTLV-1 infection (AC and patients with HAM). There is a fur-
ther expansion of these ‘ATL-like’ cells in ATL along with the presence of ATL cells. The
‘ATL-like’ cells from non-dominant clones have a distinct cytokine producing pattern and
contribute directly to the plasma cytokine profile in both non-malignant HTLV-1 infection
and possibly in ATL. The ‘ATL-like’ cells of the dominant clone (the putative ATL cells)
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possess little or no cytokines producing capability. There was progressive loss of pro-inflam-
matory cytokine producing capacity from non-ATL (uninfected) through ‘ATL-like’
(infected) to ATL (malignant) cells and we hypothesise that this represents stages in the
transformation process.
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